Peer-reviewed veterinary case report
Lymphocyte to monocyte ratio predicts survival in dogs with lymphoma
By Marconato, Laura et al.·Published in Veterinary journal (London, England : 1997)·2015·Centro Oncologico Veterinario, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Peripheral blood lymphocyte/monocyte ratio as a useful prognostic factor in dogs with diffuse large B-cell lymphoma receiving chemoimmunotherapy.
- Species:
- dog
Plain-English summary
A group of 51 dogs with diffuse large B-cell lymphoma (a type of cancer) were treated with chemotherapy and a vaccine. Researchers looked at the lymphocyte/monocyte ratio (LMR) in their blood to see if it could predict how well the dogs would do. They found that dogs with a low LMR (1.2 or less) had shorter survival times and were more likely to have their cancer return. This suggests that checking the LMR at diagnosis can help veterinarians understand a dog's prognosis better.
People also search for: dog lymphoma treatment · diffuse large B-cell lymphoma in dogs · lymphocyte monocyte ratio in dogs
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most frequent canine lymphoid neoplasm. Despite treatment, the majority of dogs with DLBCL experience tumour relapse and consequently die, so practical models to characterise dogs with a poor prognosis are needed. This study examined whether the lymphocyte/monocyte ratio (LMR) can predict outcome in dogs with newly diagnosed DLBCL with regard to time-to-progression (TTP) and lymphoma specific survival (LSS). A retrospective study analysed the prognostic significance of LMR obtained at diagnosis by flow cytometry (based on morphological properties and CD45 expression) in 51 dogs that underwent complete staging and received the same treatment, comprising multi-agent chemotherapy and administration of an autologous vaccine. Dogs with an LMR ≤ 1.2 (30% of all cases) were found to have significantly shorter TTP and LSS, and it was concluded that LMR was a useful independent prognostic indicator with biological relevance in dogs with DLBCL treated with chemoimmunotherapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26403958/